Nasdaq nmra.

The latest price target for Neumora Therapeutics ( NASDAQ: NMRA) was reported by JP Morgan on Tuesday, October 10, 2023. The analyst firm set a price target for 21.00 expecting NMRA to rise to ... According to the issued ratings of 6 analysts in the last year, the consensus rating for Neumora Therapeutics stock is Buy based on the current 6 buy ratings for NMRA. The average twelve-month price prediction for Neumora Therapeutics is $22.67 with a high price target of $26.00 and a low price target of $18.00.Insiders and Institutions Are Buying These Robot Stocks. This page (NASDAQ:NMRA) was last updated on 11/24/2023 by MarketBeat.com Staff. Adding. Choose a ...Sep 21, 2023 · Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for ...

Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...Neumora Therapeutics press release (NASDAQ:NMRA): Q3 GAAP EPS of -$1.14 misses by $0.74. $519.5 million in cash, cash equivalents and marketable securities expected to support operations into 2026.Sep 28, 2023 · VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...

CGC. Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Find the latest SEC Filings data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical ...Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines. WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company …Within the last quarter, Neumora Therapeutics (NASDAQ:NMRA) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Neumora ...The latest price target for Structure Therapeutics ( NASDAQ: GPCR) was reported by JMP Securities on Monday, November 20, 2023. The analyst firm set a price target for 91.00 expecting GPCR to rise ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th.

Nov 20, 2023 · Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical ...Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.... (NASDAQ: NMRA), and Syllable Life Sciences (acquired by Neumora). Portfolio. Atalanta Therapeutics. Atalanta Therapeutics is a biotechnology company pioneering ...Veja a previsão de preço das ações da Neumora Therapeutics, Inc. para 1 ano, feita pelos analistas e compare-a com as mudanças de preço ao longo do tempo para desenvolver …Nov 20, 2023 · Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.

NMRA | Complete Neumora Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.View real-time NMRA stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.CGC. Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Find the latest SEC Filings data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.

Nov 24, 2023 · Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ...

Nov 27, 2023 · The latest price target for Structure Therapeutics ( NASDAQ: GPCR) was reported by JMP Securities on Monday, November 20, 2023. The analyst firm set a price target for 91.00 expecting GPCR to rise ... Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...Common Stock stock price (NMRA). NASDAQ: NMRA. Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you ...Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Nov 27, 2023 · 1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, expenses and ... About the Price/ Earnings & PEG Ratios. Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ...Quais ferramentas de análise técnica podem ser usadas para analisar Neumora Therapeutics, Inc.? Confira vários osciladores, médias móveis e outros indicadores técnicos no TradingView.WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI …See the latest Neumora Therapeutics Inc stock price (NMRA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

15 Sep 2023 ... View today's Neumora Therapeutics Inc stock price and latest NMRA news and analysis. Create real-time notifications to follow any changes in ...

Visualize o gráfico de Neumora Therapeutics, Inc. ao vivo para acompanhar o movimento do preço de suas ações. Encontre previsões de mercado, NMRA finanças e notícias do mercado.

NMRA Neumora Therapeutics Inc Form 8-K - Current report false 0001885522 0001885522 2023-11-01 2023-11-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT R...WATERTOWN, Mass., Oct. 30, 2023 -- Neumora Therapeutics, Inc. , a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will...Member FINRA / SIPC / NYSE / NASDAQ / CBOE EDGX. Webull offers NMRA Ent Holdg (NMRA) historical stock prices, in-depth market analysis, NASDAQ: NMRA real-time stock quote data, in-depth charts, free NMRA options chain data, and a fully built financial calendar to help you invest smart. Buy NMRA stock at Webull. View live Neumora Therapeutics, Inc. chart to track its stock's price action. Find market predictions, NMRA financials and market news.Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...Atomera Inc (NASDAQ:ATOM)’s traded shares stood at 0.16 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $6.97, to imply an increase of 0.29% or $0.02 in intraday trading. The ATOM share’s 52-week high remains $10.72 ...Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines. WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company …Neumora Therapeutics. 's revenue in 2023 is N/A.. On average, 1 Wall Street analysts forecast NMRA's revenue for 2026 to be $3,327,405,256, with the lowest NMRA revenue forecast at $3,327,405,256, and the highest NMRA revenue forecast at $3,327,405,256.View Your Watchlist. Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and …Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.NASDAQ:NMRA; Company Type For Profit. Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain ...

Nov 8, 2023 · Within the last quarter, Neumora Therapeutics (NASDAQ:NMRA) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Neumora ... The latest Neumora Therapeutics stock prices, stock quotes, news, and NMRA history to help you invest and trade smarter. ... (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company ...NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders.Instagram:https://instagram. stock options newsletterscarvana sotckis blue cross a good insurancecummins stock price Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.View live Neumora Therapeutics, Inc. chart to track its stock's price action. Find market predictions, NMRA financials and market news. robinhood day trading cash accountshould i buy apple stock US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ... schwab high dividend etf US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI …